EMEA-001624-PIP01-14-M06 - paediatric investigation plan

Nemolizumab

Key facts

• Active Substance:
  Nemolizumab
• Therapeutic area:
  Dermatology
• Decision number:
  P/0277/2023
• PIP number:
  EMEA-001624-PIP01-14-M06
• Pharmaceutical form(s):
  Powder for solution for injection
• Condition(s) / indication(s):
  Treatment of atopic dermatitis
• Route(s) of administration:
  Subcutaneous use
• Contact for public enquiries:

  Galderma International S.A.S; E-mail: [e-mail] ; Tel.: [phone]

• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  14/07/2023

Decision

P/0277/2023 : EMA decision of 14 July 2023 on the acceptance of a modification of an agreed paediatric investigation plan for nemolizumab (EMEA- 001624-PIP01-14-M06)

Reference Number: EMA/282809/2023